

DAFTAR PUSTAKA

- Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, Kweon IY, O'Neil WM, Saikia TK & Wang J, 2009. Chronic myeloid leukemia in Asia. *International Journal of Hematology*, 89(1):14-23. doi: 10.1007/s12185-008-0230-0.
- Australian Institute of Health and Welfare (AIHW), 2005. Chronic kidney disease in Australia 2005. AIHW Cat No PHE 68, Canberra.
- American Diabetes Association (ADA), 2014. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, 37(S1): S14-18.
- Bakta IM, 2007. Hematologi Klinik Ringkas. EGC, Jakarta.
- Barta VS, Uppal NN, Pullman JM, Levy AT & Jhaveri KD, 2017. Acute tubular injury associated with imatinib (Gleevec): a case report and review of the literature. *Journal of Onco-Nephrology*, 1(1): 57-61. DOI: 10.5301/jon.5000008.
- Bienholz A, Wilde B & Kribben A, 2015. *From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injury*. *Clinical Kidney Journal*, 8(4): 405–414. doi: 10.1093/ckj/sfv043.
- Bollmann PW & del Giglio A, 2011. Chronic myeloid leukemia: past, present, future. *Einstein*, 9(2 Pt 1):236-243.
- Carter JL, Stevens PE, Irving JE & Lamb EJ, 2011. Estimating glomerular filtration rate: comparison of the CKD-EPI and MDRD equations in a large UK cohort with particular emphasis on the effect of age. *Quarter Journal Medicine*, 104: 839-47. doi: 10.1093/qjmed/hcr077.
- Chang H & Shih LY, 2008. Imatinib induced tumor lysis syndrome: report of a case and review of the literature. *Chang Gung Medical Journal*, 31(5): 510-514.
- Dahlan MS, 2016. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan. Salemba Medika, Jakarta.
- Deinum J & Derkx FHM, 2000. Cystatin for estimation of glomerular filtration rate? *Lancet*, 356: 1624-5.
- De Kogel CE & Schellens JHM, 2007. Imatinib. *The Oncologist*, 12(12): 1390-1394. doi: 10.1634/theoncologist.12-12-1390.

- Delanaye P & Mariat C, 2013. The applicability of eGFR equations to different populations. *Nature Reviews Nephrology*, 9(9): 513-22. doi: 10.1038/nrneph.2013.143.
- Dharnidharka VR, Kwon C & Stevens G, 2002. Serum Cystatin C is superior to serum creatinine as a marker of kidney function: A meta analysis. *American Journal of Kidney Diseases*, 40(2): 221-226.
- Dine A, 2012. *Renal physiology anatomy and physiology*. Addison Weisley, USA. pp.78-90.
- Druker BJ, Talpaz M & Resta DJ, 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *New England Journal of Medicine*, 344(14): 1031-1037.
- Druker BJ, Guihot F, O'Brien SG, Gathman I, Kantarjian H & IRIS investigators, 2006. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. *New England Journal of Medicine*, 355: 2408-2417. DOI: 10.1056/NEJMoa062867.
- Edmund L, 2010. *Kidney function tests. Clinical chemistry and molecular diagnosis*. 4th ed. Elsevier, America. p.797-831.
- Earley A, Miskulin D, Lamb EJ, Levey AS & Uhlig K, 2012. Estimating Equations for Glomerular Filtration Rate in the Era of Creatinine Standardization. *Annals of Internal Medicine*, 156: 785–795.
- Fadjari H & Sukrisman L, 2014. *Leukemia Granulositik Kronis*. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, M. Simadibrata, & S. Setiati (Eds.), *Buku Ajar Ilmu Penyakit Dalam* 6th ed. Interna Publishing, Jakarta. pp.1209–1213
- Flynn KE & Atallah E, 2016. Quality of life and long term therapy in patients with chronic myeloid leukemia. *Current Hematology Malignancy Report*, 11(2): 80–85. doi:10.1007/s11899-016-0306-5.
- Fored CM, Stewart JH & Dickman PW, 2003. The analgesic syndrome. In: Stewart JH, ed. *Analgesic and NSAID-induced kidney disease*. Oxford University Press, Oxford England.
- Frank C, 2010. *Biomarkers of impaired renal function*. Wolters Kluwer Health, Netherlands. pp.525-537.
- Frazer R, Irvine AE & McMullin MF, 2007. Chronic Myeloid Leukaemia in The 21st Century. *The Ulster Medical Journal*, 76(1): 8-17.
- Gaedeke, 2000. *Renal function test in Laboratory and diagnostic test handbook*. Addison Wesley, New York. pp.706-715.

- Gafter-Gvili A, Ram R, Gafter U, Shpilberg O & Raanani P, 2010. Renal failure associated with tyrosine kinase inhibitorsecase report and review of the literature. *Leukimia Research*, 34(1): 123-127.
- Gibbons J, Egorin MJ, Ramanathan RK, Fu P, Mulkerin DL, Shibata S, Takimoto CHM, Mani S, LoRusso PA, Grem JL, Pavlick A, Lenz HJ, Flick SM, Reynolds S, Lagattuta TF, Parise RA, Wang Y, Murgo AJ, Ivy SP & Remick sc, 2008. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. *Journal of Clinical Oncology*, 26: 570-576.
- Gordon JK, Magid SK, Maki RG, Fleisher M & Berman E, 2010. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). *Leukemia Research*, 34: 827–829.
- Hsieh M & Power DA, 2009. Abnormal Renal Function and Electrolyte Disturbance in Older people. *Journal of Pharmacy Practice and Research*, 39(3): 230-234.
- Hoffbrand AV, Pettit JE & Moss PAH, 2005. *Kapita selekta hematologi*. Ed 4. EGC, Jakarta. pp.167-175.
- Huang XL, Cortes J & Kantarjian H, 2012. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. *Cancer*, 118: 3123-3127.
- Irshad, 2011. Estimation of glomerular filtration rate. *Nephrology*, pp.121-128.
- Iqbal N & Iqbal N. 2014. Imatinib: A Breakthrough of Targeted Therapy in Cancer. *Chemotherapy Research and Practice*, Article ID 357027. <http://dx.doi.org/10.1155/2014/357027>.
- Jahan N & Ferdousi S, 2013. Cystatin C - a Promising Marker of Glomerular Filtration Rate. *Bangladesh Journal of Medical Biochemistry*, 6(1): 26–30.
- Jabbour E & Kantarjian H, 2016. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. *American Journal of Hematology*, 91(2): 252-265. doi: 10.1002/ajh.24275.
- Jabbour E, Cortes JE, Ghanem H, O'Brien S & Kantarjian H, 2008. Targeted Therapyin Chronic Myeloid Leukemia. *Expert Review of Anticancer Therapy*, 8(1): 99-110.
- Jhaver KD, Wanchoo R, Sakhiya V, Ross DW & Fishbane S, 2017. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. *Kidney International Reports*, 2(1): 108-123.

- Kara A, 2012. Renal function. Clinical chemistry. 6th ed. Wolters Kluwer, Philadelphia.
- Kenward R & Tan CK, 2003. Penggunaan Obat Pada Gangguan Ginjal dalam Aslam Farmasi Klinis: Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien, PT. Elex Media Komputindo Gramedia, Jakarta. pp.140-153.
- Kitiyakara C & Atichartakarn V, 2002. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. *Nephrology Dialysis Transplantation*, 17(4): 685-7. doi: 10.1093/ndt/17.4.685.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO, 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *inter.*, Suppl; 3: 1–150.
- Kotchen T, 2012. Hypertensive vascular diseases. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. *Harrison's Principle of Internal Medicine*. 18th edition. Mc Graw-Hill, New York. pp.1611-1627.
- Levey AS, Coresh J & Greene T, 2005. Expressing the MDRD study equation forestimating GFR with IDMS traceable (gold standard) serum creatinine values. *Journal of American Society of Nephrology*, 16: 69A.
- Levey AS., Inker LA & Coresh J. 2014. GFR estimation: from physiology to public health. *American Journal of Kidney Disease*, 63(5): 820-834.
- Marcolino MS, Boersma E, Clementino NCD, Macedo AV, Marx-Neto AD, Silva MHCR, van Gelder T, Akkerhuis KM & Ribeiro AL, 2011. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. *Annals of Oncology*, 22: 2073-2079.
- Mcclellan WM, & Flanders WD, 2003. Risk Factor for progressive chronic kidney disease. *Journal of American Society of Nephrology*, 14(7 Suppl 2): S65-70.
- Menon H, 2013. Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome. *South Asian Journal of Cancer*, 2(1): 38–43. doi: 10.4103/2278-330X.105893.
- Menon M, Resnick & Martin I, 2002. Urinary Lithiasis : Etiologi and Endourologi In: *Chambell's Urology 8 Ed vol.1*. W.B Saunder Company, Philadelphia. pp.3230-3292.
- Miller G, Myers GL, Ashwood ER, Killeen AA, Wang E & Thienpont LM, 2005. Creatinine measurement. *Archives of Pathology & Laboratory Medicine*, 129(3): 297-304.

- O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ & IRIS Investigators, 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *New England Journal of Medicine*, 348(11): 994-1004.
- Price & Wilson. 2006. *Patofisiologi. Konsep klinis proses-proses penyakit*. EGC, Jakarta.
- Prakash, S & O'Hare, AM, 2009. Interaction of Aging and CKD. *Seminars in nephrology*, 29(5): 497–503. doi:10.1016/j.semnephrol.2009.06.006.
- Pindolia VK & Zarowitz BJ, 2002. Imatinib Mesylate, the First Molecularly Targeted Gene Suppressor. *Pharmacotherapy*, 22(10): 1249-1265.
- Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F & Botey A, 2003. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. *Leukemia & Lymphoma*, 44(7): 1239-1241.
- Reksodiputro AH, Tadjoedin H, Supandiman I, Acang N, Kar AS, Bakta M, Benyamin AF, Ashariati A, Suharti C, Rinaldi I, Salim N, Rajabto W, Prayogo N, Tobing DL, Syampurnawati M, Kurnianda J, Maryono S, Machsoes BD, Syahrir M, Prenggono DM, Kumaat HH, Sari RM, Agustini S, Toruan TL & Akbar DF, 2015. Epidemiology study and mutation profile of patients with chronic myeloid leukemia (CML) in Indonesia. *Journal of Blood Disorder & Transfusion*, 6: 271. doi: 10.4172/2155-9864.1000271.
- Rule AD, Krambeck AE & Lieke JC, 2011. Chronic Kidney Disease in Kidney Stone Formers. *Clinical Journal of the American Society of Nephrology*, 6(8): 2069-2075. doi: 10.2215/CJN.10651110.
- Sedana MP & Wulansari TI, 2007. Penyakit Mieloproliferatif. *Jurnal Penyakit Dalam*, 8(1): 55-65.
- Sherbenou DW & Druker BJ, 2007. Applying the Discovery of the Philadelphia Chromosome. *The Journal of Clinical Investigation*, 117(8): 2067-2074.
- Smith EA, 2008. Pyelonephritis, Renal Scarring, and Reflux Nephropathy : A *Pediatrics Urologist's Perspective*. *Pediatric Radiology*, 38 Suppl 1: S76-82.
- Stevens LA, Coresh J, Greene T & Levey AS, 2006. Assessing kidney function-measured and estimated glomerular filtration rate. *New England Journal of Medicine*, 354: 2473-2483.

- Stevens L & Levey AS, 2009. Measured GFR as a confirmatory test for estimated GFR. *Journal of the American Society of Nephrology*, 20(11): 2305-13. doi: 10.1681/ASN.2009020171.
- Susalit E, 2003. Rekomendasi Baru Penatalaksanaan Penyakit Ginjal Kronik. In: *Penyakit Ginjal Kronik & Glomerulonepati: Aspek Klinik & Patologi Ginjal Pengelolaan Hipertensi Saat Ini*. Perhimpunan Nefrologi Indonesia, Jakarta. pp.1-8.
- Sukandar E, 2009. Infeksi Saluran Kemih Pasien Dewasa. In: Sudoyo, Aru W (editor). *Buku Ajar Ilmu Penyakit Dalam*. Internal Publishing, Jakarta, Indonesia. pp.1008-1014.
- Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB & Cortes J, 2010. Imatinib Front-Line Therapy Is Safe and Effective in Patients With Chronic Myelogenous Leukemia With Pre-Existing Liver and/or Renal Dysfunction. *Cancer*, 116(13): 3152–3159.
- Trela E, Glowacki S & Blasiak J, 2014. Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era? *ISRN Oncology*, Article ID 596483. doi:10.1155/2014/596483.
- Vora A, Bhutani M, Sharma A & Raina V, 2002. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. *Annals of Oncology*, 13: 1833-1834.
- Woessner DW, Lim CS & Deininger MW, 2011. Development of an Effective Therapy for CML. *Cancer Journal*, 17(6): 477-86.
- Yilmaz M, Lahoti A, O'Brien S, Noguera-Gonzalez GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H & Cortes JE, 2015. Estimated Glomerular Filtration Rate Changes in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. *American Cancer Society*, 121: 3894-3904.